Aster DM Healthcare reported a net profit of ₹106 crore for the second quarter of FY2025, marking a significant recovery from a previous loss. The company’s revenue increased by 17% to ₹1,086.4 crore compared to ₹929.4 crore in the same quarter last year. Following the announcement of these strong quarterly earnings, Aster DM Healthcare's stock surged by 13.90%, reaching ₹457.90 per share on the NSE. Similarly, Piramal Pharma's revenue also saw a year-on-year increase of 17%, reaching ₹2,242 crore, with shares rising 13% to an all-time high of ₹245 on the BSE. Other companies reporting their Q2 results include Strides Pharma, which posted a net profit of ₹93 crore, and Eris Lifesciences, which experienced a 25.8% decline in net profit to ₹91.6 crore. The overall market reaction to these earnings reports has been positive, with several healthcare stocks witnessing significant gains.